Publications:  Prof Jude Fitzgibbon

Rio-Machin A, Vulliamy T, Hug N, Walne A, Tawana K, Cardoso S, Ellison A, Pontikos N et al.(2020). The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants. Nature Communications vol. 11, (1)

Kumar EA, Okosun J, Fitzgibbon J(2020). The Biological Basis of Histologic Transformation. Hematology/Oncology Clinics of North America vol. 34, (4) 771-784.

Dokal I, Tummala H, Vulliamy T, Walne A(2020). A frameshift variant in the specificity protein 1 triggers superactivation of SP1-mediated transcription in familial bone marrow failure. Proceedings of the National Academy of Sciences of USA Article 32636268,

Araf S, Korfi K, Bewicke-Copley F, Wang J, Cogliatti S, Kumar E, Forrer F, Barrington SF et al.(2020). Genetic heterogeneity highlighted by differential FDG-PET response in diffuse large B-cell lymphoma. Haematologica vol. 105, (6) E318-E321.

Waclawiczek A, Hamilton A, Rouault-Pierre K, Abarrategi A, Albornoz MG, Miraki-Moud F, Bah N, Gribben J et al.(2020). Mesenchymal niche remodeling impairs hematopoiesis via stanniocalcin 1 in acute myeloid leukemia. Journal of Clinical Investigation vol. 130, (6) 3038-3050.

Cucco F, Barrans S, Sha C, Clipson A, Crouch S, Dobson R, Chen Z, Thompson JS et al.(2020). Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit. Leukemia vol. 34, (5) 1329-1341.

Maybury B, Fitzgibbon J, Calado D (2020). An immunocompetent, spontaneous mouse model of DLBCL for studying the response to R-CHOP and identifying new treatment targets. BRITISH JOURNAL OF HAEMATOLOGY. vol. 189, 110-111.

Fitzgibbon J, Busca A, Gloghini A, López-Guillermo A, Orazi A, Carlo-Stella C, Andrès E, Van Breda E et al.(2020). Recent Advancements in Hematology: Knowledge, Methods and Dissemination. vol. 1, (1) 5-6.

Charrot S, Armes H, Rio-Machin A, Fitzgibbon J(2020). AML through the prism of molecular genetics. British Journal of Haematology vol. 188, (1) 49-62.

Carbone A, Roulland S, Gloghini A, Younes A, von Keudell G, López-Guillermo A, Fitzgibbon J(2019). Follicular lymphoma. Nature Reviews Disease Primers vol. 5, (1)

Jurinovic V, Passerini V, Oestergaard MZ, Knapp A, Mundt K, Araf S, Richter J, Fitzgibbon J et al. (2019). Evaluation of the m7-FLIPI in Patients with Follicular Lymphoma Treated within the Gallium Trial: EZH2 mutation Status May be a Predictive Marker for Differential Efficacy of Chemotherapy. Blood. vol. 134, 122-122.

Bewicke-Copley F, Korfi K, Araf S, Kumar EA, Cummin TEC, Ashton-Key M, Barrans S, Van Hoppe S et al.(2019). Longitudinal Analyses of Diagnostic-Relapse Biopsies of Diffuse Large B Cell Lymphoma Reveal a Poor Risk Subset of ABC Patients Based on the Expression of a 30 Gene Panel. Blood vol. 134, (Supplement_1) 2769-2769.

Ortega-Molina A, Deleyto-Seldas N, Carreras J, Sanz A, Lebrero-Fernández C, Menéndez C, Vandenberg A, Fernández-Ruiz B et al.(2019). Oncogenic Rag GTPase signalling enhances B cell activation and drives follicular lymphoma sensitive to pharmacological inhibition of mTOR. Nature Metabolism vol. 1, (8) 775-789.

Araf S, Wang J, Korfi K, Pangault C, Kotsiou E, Rio-Machin A, Rahim T, Heward J et al.(2019). Correction: Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma (Leukemia, (2018), 32, 5, (1261-1265), 10.1038/s41375-018-0043-y). Leukemia vol. 33, (6)

Okosun J, Bödör C, Batlevi C, Nagy N, Michot J, Schneider T, Alizadeh H, Simon Z et al.(2019). EZH2 GAIN‐OF‐FUNCTION MUTATIONS ARE NOT ASSOCIATED WITH MORE FAVORABLE PROGNOSIS IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL): A PRELIMINARY ANALYSIS ON 590 PATIENTS. Hematological Oncology vol. 37, 192-193.

Korfi K, Araf S, Bewicke¿Copley F, Kumar E, Cummin T, Ashton¿Key M, Barrans S, Van Hoppe S et al.(2019). LONGITUDINAL ANALYSES OF DIAGNOSTIC‐RELAPSE BIOPSIES OF DIFFUSE LARGE B CELL LYMPHOMA SUGGEST THAT RELAPSE IS MEDIATED BY DISTINCT MECHANISMS IN ABC AND GCB LYMPHOMA. Hematological Oncology vol. 37, 142-143.

Kumar E, Korfi K, Bewicke-Copley F, Witzig T, Leukam M, Ansell S, Scott J, Rallis K et al.(2019). MUTATIONS AFFECTING THE CREBBP HAT DOMAIN PREDICT RESPONSE TO MTOR INHIBITORS EVEROLIMUS AND TEMSIROLIMUS IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA. HemaSphere vol. 3,

Rio-Machin A, Vulliamy T, Hug N, Caceres JF, Fitzgibbon J, Dokal I(2019). PF213 THE GENETIC LANDSCAPE OF FAMILIAL MDS/AML; RECURRING MUTATIONS IN THE RNA HELICASE DHX34 LEADING TO DEFECTS IN NONSENSE-MEDIATED RNA DECAY. HemaSphere vol. 3, (S1)

Kumar E, Korfi K, Bewicke-Copley F, Witzig T, Leukam M, Ansell S, Scott J, Rallis K et al.(2019). PF513 MUTATIONS AFFECTING THE CREBBP HAT DOMAIN PREDICT RESPONSE TO MTOR INHIBITORS EVEROLIMUS AND TEMSIROLIMUS IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA. HemaSphere vol. 3, (S1)

Bödör C, Batlevi C, Nagy N, Michot J-M, Schneider T, Alizadeh H, Simon Z, Vose J et al.(2019). PS1247 EZH2 GAIN-OF-FUNCTION MUTATIONS ARE NOT ASSOCIATED WITH MORE FAVORABLE PROGNOSIS IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: A PRELIMINARY ANALYSIS ON 590 PATIENTS. HemaSphere vol. 3, (S1) 568-569.

Heward J, Koniali L, D¿Avola A, Close K, Yeomans A, Johnson P, Okosun J, Neve R et al.(2019). S844 KDM5 INHIBITION OFFERS A NOVEL THERAPEUTIC STRATEGY FOR THE TREATMENT OF KMT2D MUTANT LYMPHOMAS. HemaSphere vol. 3, (S1) 376-377.

Araf S, Wang J, Ashton-Key M, Korfi K, Di Bella D, Rio-Machin A, Odabashian M, Foria V et al.(2019). Transmission of diffuse large B-cell lymphoma by an allogeneic stem-cell transplant. Haematologica vol. 104, (4) e174-e177.

Merron B, Kazmi-Stokes S, Cummin T, Barrans S, Araf S, Korfi K, Pascua LDL, Caddy J et al.(2019). Precision medicine for patients with lymphoma; the Bloodwise Precision Medicine for Aggressive Lymphomas (PMAL) consortium. Clinical Medicine vol. 19, (Suppl 2) 100-101.

Jakobsen JS, Laursen LG, Schuster MB, Pundhir S, Schoof E, Ge Y, D'Altri T, Vitting-Seerup K et al.(2019). Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML. Science Advances vol. 5, (7)

Brown AL, Armstrong M, Lawrence D, Wang P, Arts P, Duployez N, Churpek J, Tawana K et al.(2018). Development of a Data Portal for Aggregation and Analysis of Genomics Data in Familial Platelet Disorder with Predisposition to Myeloid Malignancy - the RUNX1.DB. Blood vol. 132, (Supplement 1) 5241-5241.

DOKAL I, TUMMALA H, VULLIAMY T(2018). homozygous OB-fold variants in telomere protein TPP1 are associated with dyskeratosis congenita-like phenotypes. Blood vol. 132, 1349-1353.

Casado P, Wilkes EH, Miraki-Moud F, Hadi MM, Rio-Machin A, Rajeeve V, Pike R, Iqbal S et al.(2018). Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells. Leukemia vol. 32, (8) 1818-1822.

Okosun J, Kridel R, Fitzgibbon J(2018). Rituximab as a first step in tackling transformation. The Lancet Haematology vol. 5, (8) e326-e327.

Heward JA, Kumar EA, Korfi K, Okosun J, Fitzgibbon J(2018). Precision medicine and lymphoma. Curr Opin Hematol vol. 25, (4) 329-334.

Araf S, Wang J, Korfi K, Pangault C, Kotsiou E, Rio-Machin A, Rahim T, Heward J et al.(2018). Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma. Leukemia vol. 32, (5) 1258-1263.

Al Seraihi AF, Rio-Machin A, Tawana K, Bödör C, Wang J, Nagano A, Heward JA, Iqbal S et al.(2018). GATA2 monoallelic expression underlies reduced penetrance in inherited GATA2-mutated MDS/AML. Leukemia vol. 32, (11) 2502-2507.

Araf S, Okosun J, Fitzgibbon J(2018). Predicting early relapse in follicular lymphoma: have we turned a corner?. The Lancet Oncology vol. 19, (4) 441-442.

Casado P, Wilkes EH, Miraki-Moud F, Hadi MM, Rio-Machin A, Rajeeve V, Pike R, Iqbal S et al.(2017). Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells. Leukemia

Araf S, Wang J, Korfi K, Pangault C, Kotsiou E, Rio-Machin A, Rahim T, Heward JA et al. (2017). Genomic Profiling Reveals Spatial Intra-Tumor Heterogeneity in Follicular Lymphoma. BLOOD. vol. 130,

Araf S, Korfi K, Nagano A, Cummin TEC, Bentley M, Thorner AR, Ashton-Key M, Calaminici M et al. (2017). Longitudinal Analyses of the Genomic, Transcriptomic, and T Cell Repertoire in Diffuse Large B Cell Lymphoma Demonstrates Changes in Signaling and Immune Recognition at Relapse. BLOOD. vol. 130,

Gascoyne RD, Nadel B, Pasqualucci L, Fitzgibbon J, Payton JE, Melnick A, Weigert O, Tarte K et al.(2017). Follicular lymphoma: State-of-the-art ICML workshop in Lugano 2015. Hematological Oncology vol. 35, (4) 397-407.

Horton SJ, Giotopoulos G, Yun H, Vohra S, Sheppard O, Bashford-Rogers R, Rashid M, Clipson A et al. (2017). Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors. Nature Cell Biology. vol. 19, 1093-1104.

Rio-Machin A, Gómez-López G, Muñoz J, Garcia-Martinez F, Maiques-Diaz A, Alvarez S, Salgado RN, Shrestha M et al.(2017). The molecular pathogenesis of the NUP98-HOXA9 fusion protein in acute myeloid leukemia. Leukemia vol. 31, (9) 2000-2005.

Tawana K, Wang J, Király PA, Kállay K, Benyó G, Zombori M, Csomor J, Al Seraihi A et al.(2017). Recurrent somatic JAK-STAT pathway variants within a RUNX1-mutated pedigree. European Journal of Human Genetics vol. 25, (8) 1020-1024.

Cummin TE, Araf S, Du M, Barrans S, Bentley MA, Clipson A, Wang M, Ahmed S et al.(2017). PROGNOSTIC SIGNIFICANCE AND CORRELATION TO GENE EXPRESSION PROFILE OF EZH2 MUTATIONS IN DIFFUSE LARGE B‐CELL LYMPHOMA (DLBL) IN 2 LARGE PROSPECTIVE STUDIES. Hematological Oncology vol. 35, (S2) 158-159.

Tawana K, Rio-Machin A, Preudhomme C, Fitzgibbon J(2017). Familial CEBPA-mutated acute myeloid leukemia. Seminars in Hematology vol. 54, (2) 87-93.

Korfi K, Ali S, Heward JA, Fitzgibbon J(2017). Follicular lymphoma, a B cell malignancy addicted to epigenetic mutations. Epigenetics vol. 12, (5) 370-377.

Casado P, Wilkes E, Hadi MM, Rajeeve V, Miraki-Moud F, Pike R, Del Rio-Machin A, Iqbal S et al. (2016). Differentiation Status Revealed By Shotgun Phosphoproteomics Determines Sensitivity of Primary AML Cells to Kinase Inhibitors. Blood. vol. 128, 840-840.

Fitzgibbon J(2016). Genomic Discovery, Prognosis, and Target Therapy Development. Blood vol. 128, (22)

Rio-Machin A, Gomez-Lopez G, Maiques-Diaz A, Alvarez S, Calasanz MJ, Fitzgibbon J, Cigudosa JC (2016). HDAC Inhibitors As Novel Targeted Therapies for NUP98-HOXA9 AML Patients. Blood. vol. 128, 2685-2685.

Noerenberg D, Mansouri L, Young E, Mareike F, Abdulla M, Asmar F, Gonzalez-Farre B, Anna T et al. (2016). NFKBIE Deletions: A Novel Marker of Clinical Aggressiveness in Primary Mediastinal B-Cell Lymphoma. BLOOD. vol. 128,

Britton DJ, Wilkes E, Casado P, Rajeeve V, Fitzgibbon J, Gribben J, Cutillas PR (2016). Proteomic Analysis Directs Effective Drug Selection in Relapsed AML By Quantifying Drug Targets. Blood. vol. 128, 5265-5265.

Al Seraihi A, Rio-Machin A, Tawana K, Bödör C, Araf S, Heward JA, Smith M, Iqbal S et al. (2016). Variable Penetrance Is Linked with Monoallelic Gene Expression in Inherited GATA2-Mutated MDS/AML. Blood. vol. 128, 3916-3916.

Noerenberg* D, Mansouri* L, Young E, Mareike F, Abdulla M, Asmar F, Gonzalez-Farre B, Anna T et al.(2016). ΝFΚΒΙΕ Deletions: A Novel Marker of Clinical Aggressiveness in Primary Mediastinal B-Cell Lymphoma. Blood vol. 128, (22) 609-609.

Stunnenberg HG, Abrignani S, Adams D, de Almeida M, Altucci L, Amin V, Amit I, Antonarakis SE et al.(2016). The International Human Epigenome Consortium: A Blueprint for Scientific Collaboration and Discovery. Cell vol. 167, (5) 1145-1149.

Mansouri L, Noerenberg D, Young E, Mylonas E, Abdulla M, Frick M, Asmar F, Ljungström V et al.(2016). Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma. Blood vol. 128, (23) 2666-2670.

Araf S, Korfi K, Rahim T, Davies A, Fitzgibbon J(2016). Advances in the molecular diagnosis of diffuse large B-cell lymphoma in the era of precision medicine. Expert Review of Molecular Diagnostics: new diagnostic technologies are set to revolutionise healthcare vol. 16, (10) 1093-1102.

Araf S, Fitzgibbon J(2016). Pediatric-type FL: Simply different. Blood vol. 128, (8) 1030-1031.

Ripperger T, Tawana K, Kratz C, Schlegelberger B, Fitzgibbon J, Steinemann D(2016). Clinical utility gene card for: Familial platelet disorder with associated myeloid malignancies. European Journal of Human Genetics vol. 24, (8) e1-e4.

Tummala H, Walne AJ, Williams M, Bockett N, Collopy L, Cardoso S, Ellison A, Wynn R et al.(2016). DNAJC21 Mutations Link a Cancer-Prone Bone Marrow Failure Syndrome to Corruption in 60S Ribosome Subunit Maturation. American Journal of Human Genetics vol. 99, (1) 115-124.

Larrea E, Fernandez-Mercado M, Ceberio I, Guerra-Assunção JA, Okosun J, Fitzgibbon J, Lawrie C(2016). 110 Follicular lymphoma cases harbour recurrent mutations in micro-RNA binding sites of genes associated with lymphomagenesis. European Journal of Cancer vol. 61, s11-s12.

Larrea E, Fernandez-Mercado M, Ceberio I, Guerra-Assuncao JA, Okosun J, Fitzgibbon J, Lawrie C (2016). Follicular lymphoma cases harbour recurrent mutations in microRNA binding sites of genes associated with lymphomagenesis. EUROPEAN JOURNAL OF CANCER. vol. 61, S11-S12.

GROSE RP, Dawkins JBN, Wang J, maniati, heward, koniali, kocher, martin et al.(2016). Reduced expression of histone methyltransferases KMT2C and KMT2D correlates with improved outcome in pancreatic ductal adenocarcinoma. Cancer Research

Araf S, Wang J, Pangault C, Kotsiou E, Hoxha E, Iqbal S, Davies J, Johnson P et al. (2016). GENOMIC PROFILING REVEALS SPATIAL HETEROGENEITY IN FOLLICULAR LYMPHOMA: IMPLICATIONS FOR PRECISION MEDICINE. HAEMATOLOGICA. vol. 101, 270-270.

Britton D, Casado P, Rajeeve V, Wilkes E, Smith R, Fitzgibbon J, Gribben J, Cutillas P (2016). PROTEOMIC ANALYSIS OF RELAPSE AML IDENTIFIES OPPORTUNITIES FOR THERAPEUTIC INTERVENTION IN INDIVIDUAL PATIENTS. HAEMATOLOGICA. vol. 101, 373-373.

Okosun J, Wolfson RL, Wang J, Araf S, Wilkins L, Castellano BM, Escudero-Ibarz L, Al Seraihi AF et al.(2016). Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma (vol 48, pg 183, 2016). NATURE GENETICS vol. 48, (6) 700-700.

Rio-Machin A, Cardoso S, Tawana K, Wang J, Chelala C, Plagnol V, Wallis Y, Ryan G et al. (2016). WHOLE EXOME SEQUENCING REVEALS NOVEL CANDIDATE GENES IN FAMILIAL MDS/AML. HAEMATOLOGICA. vol. 101, 205-206.

Okosun J, Wolfson RL, Wang J, Araf S, Wilkins L, Castellano BM, Escudero-Ibarz L, Seraihi AFA et al.(2016). Corrigendum: Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. Nat Genet vol. 48, (6) 700-700.

DOKAL I(2016). Germline heterozygous DDX41 vriants in a subset of familial myelodysplasia and acute myeloid leukaemia. Leukemia

Okosun J, Montoto S, Fitzgibbon J(2016). The routes for transformation of follicular lymphoma. Current Opinion in Hematology vol. 23, (4) 1-1.

Kotsiou E, Okosun J, Besley C, Iqbal S, Matthews J, Fitzgibbon J, Gribben J, DAVIES JK(2016). TNFRSF14 aberrations in follicular lymphoma increase clinically significant allogeneic T-cell responses. Blood vol. 128, (1) 72-81.

Strefford JC, Fitzgibbon J, Rose-Zerilli MJJ, Bödör C(2016). The genetics of mature B-cell malignancies. The Genetic Basis of Haematological Cancers,

Tawana K, Fitzgibbon J(2016). Inherited DDX41 mutations: 11 genes and counting. Blood vol. 127, (8) 960-961.

Okosun J, Wolfson RL, Wang J, Araf S, Wilkins L, Castellano BM, Escudero-Ibarz L, Al Seraihi AF et al.(2016). Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. Nature Genetics vol. 48, (2) 183-188.

Engert A, Balduini C, Brand A, Coiffier B, Cordonnier C, Döhner H, De Wit TD, Eichinger S et al.(2016). The european hematology association roadmap for european hematology research: A consensus document. Haematologica vol. 101, (2) 115-208.

Araf S, Okosun J, Koniali L, Fitzgibbon J, Heward J(2016). Epigenetic dysregulation in follicular lymphoma. Epigenomics vol. 8, (1) 77-84.

Okosun J, Wolfson RL, Wang J, Araf S, Wilkins L, Castellano BM, Escudero-Ibarz L, Al Seraihi AF et al. (2015). Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. Nature Genetics.

Tawana K, Wang J, Renneville A, Bödör C, Hills R, Loveday C, Savic A, Van Delft FW et al.(2015). Disease evolution and outcomes in familial AML with germline CEBPA mutations. Blood vol. 126, (10) 1214-1223.

Carlotti E, Wrench D, Rosignoli G, Marzec J, Sangaralingam A, Hazanov L, Michaeli M, Hallam S et al.(2015). High throughput sequencing analysis of the immunoglobulin heavy chain gene from flow-sorted B cell sub-populations define the dynamics of follicular lymphoma clonal evolution. PLoS ONE vol. 10, (9)

Tawana K, Wang J, Kiraly PA, Kallay K, Benyo G, Krivan G, Csomor J, Fitzgibbon J et al. (2015). CONVERGENCE OF SOMATIC MUTATIONS WITHIN THE JAK-STAT SIGNALLING PATHWAY IN A NOVEL RUNX1-MUTATED PEDIGREE. HAEMATOLOGICA. vol. 100, 9-10.

Koniali L, Heward J, Loveday C, Wilkins L, Ishfaq M, Wang J, Okosun J, Packham G et al. (2015). KDM5 INHIBITION LEADS TO INCREASED H3K4ME3 LEVELS AND CELL DEATH IN GERMINAL CENTRE LYMPHOMA CELL LINES INDEPENDENT OF MLL2 MUTATION STATUS. HAEMATOLOGICA. vol. 100, 104-104.

Noerenberg D, Frick M, Couronne L, Lenze D, Baldus CD, Bastard C, Okosun J, Fitzgibbon J et al. (2015). NFKBIE MUTATIONS OCCUR IN 15% OF GCB DLBCL AND IN VARIOUS OTHER LYMPHOID MALIGNANCIES. HAEMATOLOGICA. vol. 100, 549-549.

Kotsiou E, Okosun J, Clear AJ, Iqbal S, Fitzgibbon J, Gribben JG, Davies JK (2014). TNFRSF14 aberrations in Follicular Lymphoma B Cells Result in Increased Alloresponses in Vitro and in Vivo. Blood. vol. 124, 2426-2426.

Haider S, Wang J, Nagano A, Desai A, Arumugam P, Dumartin L, Fitzgibbon J, Hagemann T et al.(2014). A multi-gene signature predicts outcome in patients with pancreatic ductal adenocarcinoma. Genome Medicine vol. 6, (12)

Rohatiner AZS, Smith ML, Spinelli O, Rambaldi A, Bassan R, di Bona E, Rodeghiero F, Raimondi R et al.(2014). Myeloblative therapy with autologous haematopoietic stem cell support as consolidation of first remission in acute myeloid leukaemia - very long follow-up. Br J Haematol vol. 167, (5) 724-726.

Okosun J, Packham G, Fitzgibbon J(2014). Investigational epigenetically targeted drugs in early phase trials for the treatment of haematological malignancies. Expert Opin Investig Drugs vol. 23, (10) 1321-1332.

Bouska A, McKeithan TW, Deffenbacher KE, Lachel C, Wright GW, Iqbal J, Smith LM, Zhang W et al.(2014). Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. BLOOD vol. 123, (11) 1681-1690.

Okosun J, Bödör C, Wang J, Araf S, Yang CY, Pan C, Boller S, Cittaro D et al.(2014). Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nature Genetics vol. 46, (2) 176-181.

Okosun J, Bödör C, Wang J, Araf S, Yang C-Y, Pan C, Boller S, Cittaro D et al.(2014). Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet vol. 46, (2) 176-181.

Tawana K, Renneville A, Wang J, Georgiades P, Thomas X, Mialou V, Savic A, Van Delft FW et al. (2013). Familial AML With Germline CEBPA Mutations: Extended Clinical Outcomes and Analysis Of Secondary Mutations Using Whole Exome Sequencing. Blood. vol. 122, 740-740.

Popov N, Maniati E, Marzec J, Okosun J, Scott R, Kranz A, Stewart F, Chelala C et al. (2013). Investigating The Role Of MLL2 (Mll4) In B Cell Development. Blood. vol. 122, 343-343.

Mutsaers PGNJ, van de Loosdrecht AA, Tawana K, Bödör C, Fitzgibbon J, Menko FH(2013). Highly variable clinical manifestations in a large family with a novel GATA2 mutation. Leukemia vol. 27, (11) 2247-2248.

Bödör C, Grossmann V, Popov N, Okosun J, O'Riain C, Tan K, Marzec J, Araf S et al.(2013). EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood vol. 122, (18) 3165-3168.

Gertner-Dardenne J, Fauriat C, Orlanducci F, Thibult M-L, Pastor S, Fitzgibbon J, Bouabdallah R, Xerri L et al.(2013). The co-receptor BTLA negatively regulates human V gamma 9V delta 2 T-cell proliferation: a potential way of immune escape for lymphoma cells. BLOOD vol. 122, (6) 922-931.

Okosun J, Bödör C, Wang J, Araf S, Chelala C, Fitzgibbon J(2013). Genomic analysis reveals epigenetic ‘addiction’ underpinning follicular lymphoma and its transformation – a rationale for targeted epigenetic therapies. Clinical Epigenetics vol. 5, (Suppl 1)

Green CL, Tawana K, Hills RK, Bödör C, Fitzgibbon J, Inglott S, Ancliff P, Burnett AK et al.(2013). GATA2 mutations in sporadic and familial acute myeloid leukaemia patients with CEBPA mutations. Br J Haematol vol. 161, (5) 701-705.

Okosun J, Clear A, Iqbal S, Matthews J, Gribben J, Fitzgibbon J, Davies J (2013). TNFRSF14 aberrations are associated with death from acute GvHD after reduced-intensity conditioned allogeneic haematopoietic stem cell transplantation for follicular lymphoma. BONE MARROW TRANSPLANTATION. vol. 48, S169-S169.

Robbez-Masson LJ, Bödör C, Jones JL, Hurst HC, Fitzgibbon J, Hart IR, Grose RP(2013). Functional analysis of a breast cancer-associated FGFR2 single nucleotide polymorphism using zinc finger mediated genome editing. PLoS One vol. 8, (11)

Bouska A, McKeithan T, Deffenbacher KE, Lachel C, Wright GW, Iqbal J, Smith LM, Liu Z et al. (2012). Genetic Abnormalities in Follicular Lymphoma and Transformed Follicular Lymphoma. BLOOD. vol. 120,

Bo¿odo¿or C, Vera G, Kohlmann A, Tan K, Okosun J, Popov N, Araf S, Marzec J et al.(2012). High Incidence of EZH2 Mutations with Variable Mutation Load in Follicular Lymphoma and Its Consequences for EZH2 Targeted Therapy. Blood vol. 120, (21) 545-545.

Okosun J, Boedoer C, Wang J, Araf S, Marzec J, Iqbal S, Matthews J, Calaminici M et al. (2012). Whole Genome Sequencing in Sequential Biopsies Reveals the Genetic Evolution of Follicular Lymphoma to Transformed Follicular Lymphoma. BLOOD. vol. 120,

Delage B, Luong P, Maharaj L, O'Riain C, Syed N, Crook T, Hatzimichael E, Papoudou-Bai A et al.(2012). Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis. Cell Death Dis vol. 3,

Quintana-Bustamante O, Smith SL-L, Griessinger E, Reyal Y, Vargaftig J, Lister TA, Fitzgibbon J, Bonnet D(2012). Overexpression of wild-type or mutants forms of CEBPA alter normal human hematopoiesis. LEUKEMIA vol. 26, (7) 1537-1546.

Bödör C, Renneville A, Smith M, Charazac A, Iqbal S, Etancelin P, Cavenagh J, Barnett MJ et al.(2012). Germ-line GATA2 p.THR354MET mutation in familial myelodysplastic syndrome with acquired monosomy 7 and ASXL1 mutation demonstrating rapid onset and poor survival. Haematologica vol. 97, (6) 890-894.

Adams D, Altucci L, Antonarakis SE, Ballesteros J, Beck S, Bird A, Bock C, Boehm B et al.(2012). BLUEPRINT to decode the epigenetic signature written in blood. NATURE BIOTECHNOLOGY vol. 30, (3) 224-226.

Leich E, Zamo A, Horn H, Haralambieva E, Puppe B, Gascoyne RD, Chan W-C, Braziel RM et al.(2011). MicroRNA profiles of t(14;18)-negative follicular lymphoma support a late germinal center B-cell phenotype. Blood vol. 118, (20) 5550-5558.

Okosun J, Fitzgibbon J(2011). It's a targeted world in non-Hodgkin's lymphoma. Br J Nurs vol. 20, (17)

Okosun J, Fitzgibbon J(2011). It's a targeted world in non-Hodgkin's lymphoma. British Journal of Nursing vol. 20, (17 SUPPL.)

Fitzgibbon J (2011). A Molecular Portrait of Follicular Lymphoma. EUROPEAN JOURNAL OF CANCER. vol. 47, S33-S33.

Stevens J, Waters R, Sieniawska C, Kassam S, Montoto S, Fitzgibbon J, Rohatiner A, Lister A et al.(2011). Serum selenium concentration at diagnosis and outcome in patients with haematological malignancies. Br J Haematol vol. 154, (4) 448-456.

Montoto S, Fitzgibbon J(2011). Transformation of indolent B-cell lymphomas. J Clin Oncol vol. 29, (14) 1827-1834.

Szlosarek PW, Luong F, Clear A, Taussig D, Joel S, Calaminici M, Debernardi S, Fitzgibbon J et al.(2011). Abstract 4067: Pegylated arginine deiminase (ADI-PEG20) as a potential novel therapy for argininosuccinate synthetase-deficient acute myeloid leukemia. 4067-4067.

Szlosarek PW, Luong F, Clear A, Taussig D, Joel S, Calaminici M, Debernardi S, Fitzgibbon J et al.(2011). Pegylated arginine deiminase (ADI-PEG20) as a potential novel therapy for argininosuccinate synthetase-deficient acute myeloid leukemia. CANCER RESEARCH vol. 71,

Bödör C, O'Riain C, Wrench D, Matthews J, Iyengar S, Tayyib H, Calaminici M, Clear A et al.(2011). EZH2 Y641 mutations in follicular lymphoma. Leukemia vol. 25, (4) 726-729.

Wrench D, Leighton P, Skibola CF, Conde L, Cazier J-B, Matthews J, Iqbal S, Carlotti E et al.(2011). SNP rs6457327 in the HLA region on chromosome 6p is predictive of the transformation of follicular lymphoma. Blood vol. 117, (11) 3147-3150.

Langabeer SE, Owen CJ, McCarron SL, Fitzgibbon J, Smith OP, O'Marcaigh A, Browne P(2010). A novel RUNX1 mutation in a kindred with familial platelet disorder with propensity to acute myeloid leukaemia: male predominance of affected individuals. Eur J Haematol vol. 85, (6) 552-553.

Wrench D, Sangaralingam A, Tayyib H, Kang MK, Riain C, Gupta M, Carlotti E, Bodor C et al. (2010). TNFRSF14 and EZH2 Mutations, Chr2p Gain and Copy Number Changes Targeting Genes Whose Proteins Interact with the Microenvironment In Transformed Follicular Lymphoma. BLOOD. vol. 116, 349-349.

Wrench D, Montoto S, Fitzgibbon J(2010). Molecular signatures in the diagnosis and management of follicular lymphoma. Curr Opin Hematol vol. 17, (4) 333-340.

Ghazaly E, Smith P, Quentmeier H, Drexler H, Iqbal S, Taussig D, Young B, Lister A et al. (2010). ACCUMULATION OF 2-HYDROXYGLUTARATE (2-HG) IN NORMAL KARYOTYPE AML PATIENTS WITH IDH1 MUTATION. HAEMATOLOGICA. vol. 95, 20-20.

O'Riain C, Smith P, Clear A, Wrench D, Gupta M, Bodor C, Matolcsy A, Calaminici M et al. (2010). EZH2 MUTATION IN FOLLICULAR LYMPHOMA. HAEMATOLOGICA. vol. 95, 167-167.

Wrench J, Skibola C, Matthews J, Cazier JB, Iqbal S, Carlotti E, Calaminici M, Davies A et al. (2010). SNP RS6457327 ON CHROMOSOME 6P PREDICTS TRANSFORMATION OF FOLLICULAR LYMPHOMA. HAEMATOLOGICA. vol. 95, 170-171.

Ghazaly E, Smith P, Quentmeier H, Drexler H, Iqbal S, Taussig D, Young B, Lister A et al. (2010). ACCUMULATION OF 2-HYDROXYGLUTARATE (2-HG) IN NORMAL KARYOTYPE AML PATIENTS WITH IDH1 MUTATION. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. vol. 95, 20-20.

O' Riain C, Smith P, Clear A, Wrench D, Gupta M, Bodor C, Matolcsy A, Calaminici M et al. (2010). EZH2 MUTATION IN FOLLICULAR LYMPHOMA. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. vol. 95, 167-167.

Wrench J, Skibola C, Matthews J, Cazier JB, Iqbal S, Carlotti E, Calaminici M, Davies A et al. (2010). SNP RS6457327 ON CHROMOSOME 6P PREDICTS TRANSFORMATION OF FOLLICULAR LYMPHOMA. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. vol. 95, 170-171.

Szlosarek PW, Delage B, O'Riain C, Hatzimichael E, Crook T, Calaminici M, Gribben JG, Lemoine N et al.(2010). Effect of inactivation of argininosuccinate synthetase on sensitivity of lymphomas to caspase-dependent apoptosis following treatment with arginine deiminase. Journal of Clinical Oncology vol. 28, (15_suppl) 8093-8093.

Langabeer SE, Owen CJ, McCarron SL, Fitzgibbon J, O'Marcaigh A, Browne P (2010). A novel RUNX1 mutation in an Irish kindred with familial platelet disorder with propensity to acute myeloid leukaemia. BRITISH JOURNAL OF HAEMATOLOGY. vol. 149, 73-73.

Owen CJ, Fitzgibbon J(2010). The Genetics of Acute Myeloid Leukemias. Molecular Hematology: Third Edition,

Owen C, Fitzgibbon J, Paschka P(2010). The clinical relevance of Wilms Tumour 1 (WT1) gene mutations in acute leukaemia. HEMATOL ONCOL vol. 28, (1) 13-19.

O'Riain C, Calaminici M, Clear A, Braziel RM, Gascoyne RD, Rosenwald A, Campo E, Smeland EB et al. (2010). DNA Methylation and Polycomb Repression in Follicular Lymphoma. MODERN PATHOLOGY. vol. 23, 315A-315A.

O'Riain C, O'Shea DM, Yang Y, Le Dieu R, Gribben JG, Summers K, Yeboah-Afari J, Bhaw-Rosun L et al.(2009). Array-based DNA methylation profiling in follicular lymphoma. Leukemia vol. 23, (10) 1858-1866.

Fitzgibbon J (2009). The Molecular Pathogenesis of Follicular Lymphoma. JOURNAL OF MEDICAL GENETICS. vol. 46, S24-S24.

Leich E, Salaverria I, Bea S, Zettl A, Wright G, Moreno V, Gascoyne RD, Chan WC et al.(2009). Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. BLOOD vol. 114, (4) 826-834.

Oke A, Pearce D, Wilkinson RW, Crafter C, Odedra R, Cavenagh J, Fitzgibbon J, Lister AT et al.(2009). AZD1152 Rapidly and Negatively Affects the Growth and Survival of Human Acute Myeloid Leukemia Cells In vitro and In vivo. CANCER RES vol. 69, (10) 4150-4158.

Carlotti E, Wrench D, Matthews J, Iqbal S, Davies A, Norton A, Hart J, Lai R et al.(2009). Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone. Blood vol. 113, (15) 3553-3557.

O'Shea D, O'Riain C, Gupta M, Waters R, Yang Y, Wrench D, Gribben J, Rosenwald A et al.(2009). Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation. Blood vol. 113, (10) 2298-2301.

Fitzgibbon J, Gale R, Hills R, Virappane P, Burnett A, Lister TA, Linch D(2009). Comparing Apples and Oranges in Normal Karyotype Acute Myeloid Leukemia REPLY. J CLIN ONCOL vol. 27, (3) 474-476.

Wrench D, Waters R, Carlotti E, Iqbal S, Matthews J, Calaminici M, Gribben J, Lister TA et al.(2009). Clinical relevance of MDM2 SNP 309 and TP53 Arg72Pro in follicular lymphoma. HAEMATOL-HEMATOL J vol. 94, (1) 148-150.

Owen CJ, Toze CL, Koochin A, Forrest DL, Smith CA, Stevens JM, Jackson SC, Poon M-C et al.(2008). Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. Blood vol. 112, (12) 4639-4645.

Virappane P, Gale R, Hills R, Kakkas I, Summers K, Stevens J, Allen C, Green C et al. (2008). Mutation of the Wilms' Tumor 1 Gene Is a Poor Prognostic Factor Associated With Chemotherapy Resistance in Normal Karyotype Acute Myeloid Leukemia: The United Kingdom Medical Research Council Adult Leukaemia Working Party. JOURNAL OF CLINICAL ONCOLOGY. vol. 26, 5429-5435.

Deffenbacher KE, Wright G, Iqbal J, Geng HM, O'Shea D, Lister TA, Fitzgibbon J, Fu K et al. (2008). Genetic Abnormalities Involved in the Development and Progression of Follicular Lymphoma. BLOOD. vol. 112, 714-714.

Deffenbacher KE, Wright G, Iqbal J, Geng H, O¿Shea D, Lister TA, Fitzgibbon J, Fu K et al.(2008). Genetic Abnormalities Involved in the Development and Progression of Follicular Lymphoma. Blood vol. 112, (11) 2049-2049.

Yang YW, Wrench DJ, Lister TA, Fitzgibbon J (2008). Recurrent Chromosomal Intermingling Interactions at the BCL2 Locus in T(14;18) +Ve and -Ve Cell Lines. BLOOD. vol. 112, 713-713.

Yang Y, Wrench DJ, Lister TA, Fitzgibbon J(2008). Recurrent Chromosomal Intermingling Interactions at the BCL2 Locus in T(14;18) +Ve and −Ve Cell Lines. Blood vol. 112, (11) 2048-2048.

Quintana-Bustamante O, Smith SLL, Fitzgibbon J, Bonnet D (2008). Role of Different C/EBP alpha Mutations in AML Transformation. BLOOD. vol. 112, 484-484.

Quintana-Bustamante O, Smith SL-L, Fitzgibbon J, Bonnet D(2008). Role of Different C/EBPα Mutations in AML Transformation. Blood vol. 112, (11) 1343-1343.

O'Shea D, O'Riain C, Taylor C, Waters R, Carlotti E, Macdougall F, Gribben J, Rosenwald A et al.(2008). The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. Blood vol. 112, (8) 3126-3129.

Raghavan M, Smith L-L, Lillington DM, Chaplin T, Kakkas I, Molloy G, Chelala C, Cazier J-B et al.(2008). Segmental uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid leukemia. Blood vol. 112, (3) 814-821.

Stevens JM, Waters R, Sieniawska C, Rohatiner A, Fitzgibbon J, Joel SP, Lister TA (2008). ASSOCIATION OF SERUM SELENIUM AT PRESENTATION, PATIENT CHARACTERISTICS AND OUTCOME IN HODGKIN AND FOLLICULAR LYMPHOMA. HAEMATOLOGICA. vol. 93, 249-249.

Stevens JM, Juliger S, Summers K, Fitzgibbon J, Lister TA, Joel SP (2008). METHYLSELENINIC ACID DEMONSTRATES ANTI-LEUKAEMIC ACTIVITY AND SENSITISES AML CELLS TO THE EFFECTS OF CYTOTOXIC AGENTS BY INITIATING THE UNFOLDED PROTEIN RESPONSE. HAEMATOLOGICA. vol. 93, 115-116.

Wrench D, Waters R, Matthews J, Calaminici M, Carlotti E, Iqbal S, Gribben J, Lister A et al. (2008). MDM2 309 and TP53 ARG72PRO SNP genotypes do not predict clinical outcome of follicular lymphoma. ANNALS OF ONCOLOGY. vol. 19, 178-178.

Stevens JM, Juliger S, Summers K, Fitzgibbon J, Lister TA, Joel SP (2008). METHYLSELENINIC ACID DEMONSTRATES ANTI-LEUKAEMIC ACTIVITY AND SENSITISES AML CELLS TO THE EFFECTS OF CYTOTOXIC AGENTS BY INITIATING THE UNFOLDED PROTEIN RESPONSE. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. vol. 93, 115-116.

O'Riain C, O'Shea D, Yang Y, Gribben J, Afari J, Mein CA, Crook T, Smith P et al. (2008). Methylation profiling in 158 cases of previously untreated follicular lymphoma (FL). ANNALS OF ONCOLOGY. vol. 19, 101-101.

O'Shea D, O'Riain C, MacDougall F, Gribben J, Young BD, Rosenwald A, Rimsza L, Roberts R et al. (2008). SNP array genotyping in 182 diagnostic follicular lymphoma cases identifies sites of AUPD associated with overall survival and risk of transformation. ANNALS OF ONCOLOGY. vol. 19, 111-111.

Owen C, Virappane P, Alikian M, Stasevich I, Summers K, Lillington D, Bonnet D, Burnett A et al.(2008). WTX is rarely mutated in acute myeloid leukemia. HAEMATOL-HEMATOL J vol. 93, (6) 947-948.

Owen CJ, Toze CJ, Forrest DL, Macheta A, Smith CA, Barnett MJ, Yin JAL, Lister TA et al.(2008). Should patients with myelodysplasia and/or acute myeloid leukemia (MDS/AML) be screened for inherited runx1 mutations prior to sibling donor allografting?. ANN HEMATOL vol. 87, S11-S11.

Owen C, Barnett M, Fitzgibbon J(2008). Familial myelodysplasia and acute myeloid leukaemia--a review. Br J Haematol vol. 140, (2) 123-132.

Carlotti E, Wrench D, Iqbal S, O¿Shea D, Davies A, Virappane P, Hart J, Lai R et al.(2007). Determining the Mechanism of Transformation of Follicular Lymphoma into Diffuse Large B Cell Lymphoma. Blood vol. 110, (11) 181-181.

Carlotti E, Wrench D, Iqbal S, O'Shea D, Davies A, Virappane P, Hart J, Lai R et al. (2007). Determining the mechanism of transformation of follicular lymphoma into diffuse large B cell lymphoma. BLOOD. vol. 110, 61A-61A.

Virappane P, Gale RE, Hills R, Kakkas I, Summers K, Stevens J, Green C, Allen C et al. (2007). Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemoresistance in normal karyotype acute myeloid leukemia. BLOOD. vol. 110, 113A-113A.

Virappane P, Gale RE, Hills R, Kakkas I, Summers K, Stevens J, Green C, Allen C et al.(2007). Mutation of the Wilms’ Tumor 1 Gene Is a Poor Prognostic Factor Associated with Chemoresistance in Normal Karyotype Acute Myeloid Leukemia. Blood vol. 110, (11) 361-361.

Owen CJ, Yin JAL, Toze CJ, Forrest DL, Macheta A, Smith CA, Barnett MJ, Lister TA et al. (2007). Should patients with myelodysplasia and/or acute myeloid leukemia (MDS/AML) be screened for inherited RUNX1 mutations prior to sibling donor allografting?. BLOOD. vol. 110, 336B-336B.

Jüliger S, Goenaga-Infante H, Lister TA, Fitzgibbon J, Joel SP(2007). Chemosensitization of B-cell lymphomas by methylseleninic acid involves nuclear factor-kappaB inhibition and the rapid generation of other selenium species. Cancer Res vol. 67, (22) 10984-10992.

Fitzgibbon J, Iqbal S, Davies A, O'shea D, Carlotti E, Chaplin T, Matthews J, Raghavan M et al.(2007). Genome-wide detection of recurring sites of uniparental disomy in follicular and transformed follicular lymphoma. Leukemia vol. 21, (7) 1514-1520.

Owen C, Stevens J, Amess J, Chaplin T, Cavenagh J, Lillington D, Young BD, Lister TA et al. (2007). Familial myelodysplasia with monosomy 7. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. vol. 92, 234-234.

O'Shea D, Iqbal S, Carlotti E, Davies A, Chaplin T, Matthews J, Manoj M, Norton A et al. (2007). SNP array profiling of follicular lymphoma reveals novel regions of acquired UPD. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. vol. 92, 62-62.

Kakkas I, Summers K, Fleischmann C, Virappane P, Lister TA, Fitzgibbon J (2007). Simultaneous detection of FLT3, NPM1 and WT1 mutations using high-resolution capillary electrophoresis. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. vol. 92, 370-370.

Virappane P, Gale RE, Hills RK, Kakkas K, Summers K, Stevens J, Green CL, Allen CG et al. (2007). Wilms' tumour 1 mutation in normal karyotype aml. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. vol. 92, 19-20.

Raghavan M, Smith LL, Chaplin T, Lillington D, Molloy G, Kakkas I, Chelala C, Cazier JB et al. (2007). Frequent relapse of acute myeloid leukaemia by mitotic recombination. BRITISH JOURNAL OF HAEMATOLOGY. vol. 137, 25-25.

Juliger S, Joel SP, Fitzgibbon J, Lister TA (2007). Serum selenium at presentation may predict disease outcome in acute myeloid leukaemia (AML). BRITISH JOURNAL OF HAEMATOLOGY. vol. 137, 65-65.

Davies AJ, Rosenwald A, Wright G, Lee A, Last KW, Weisenburger DD, Chan WC, Delabie J et al.(2007). Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. BRIT J HAEMATOL vol. 136, (2) 286-293.

Summers K, Stevens J, Kakkas I, Smith M, Smith LL, MacDougall F, Cavenagh J, Bonnet D et al.(2007). Wilms' tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML [1]. Leukemia vol. 21, (3) 550-551.

O'Shea D, Iqbal S, Carlotti E, Davies A, Chaplin T, Matthews J, Raghavan M, Norton A et al. (2006). aUPD in the clonal evolution of follicular lymphoma. BLOOD. vol. 108, 585A-585A.

Last K, Maharaj L, Perry J, Strauss S, Fitzgibbon J, Lister TA, Joel S(2006). The activity of methylated and non-methylated selenium species in lymphoma cell lines and primary tumours. ANN ONCOL vol. 17, (5) 773-779.

Zhang LY, Smith ML, Schultheis B, Fitzgibbon J, Lister TA, Melo JV, Cross NCP, Cavenagh JD(2006). A novel K5091 mutation of KIT identified in familial mastocytosis - in vitro and in vivo responsiveness to imatinib therapy. LEUKEMIA RES vol. 30, (4) 373-378.

Smith LL, Pearce D, Smith ML, Jenner M, Lister TA, Bonnet D, Goff L, Fitzgibbon J(2006). Development of a quantitative real-time polymerase chain reaction method for monitoring CEBPA mutations in normal karyotype acute myeloid leukaemia. BRIT J HAEMATOL vol. 133, (1) 103-105.

Juliger S, Goenaga-Infante H, Fitzgibbon J, Lister AT, Joel SP(2005). Methylseleninic Acid Results in Rapid Changes in Intracellular Selenium Species and Sensitises Human Lymphoma Cells to Doxorubicin. Blood vol. 106, (11) 1768-1768.

Juliger S, Goenaga-Infante H, Fitzgibbon J, Lister AT, Joel SP (2005). Methylseleninic acid results in rapid changes in intracellular selenium species and sensitises human lymphoma cells to doxorubicin. BLOOD. vol. 106, 503A-503A.

Joel SP, Oke A, Foot N, Keen N, Bonnet D, Lister TA, Fitzgibbon J (2005). The activity of the novel aurora kinase B inhibitor AZD1152 in acute myeloid leukaemia cells. BLOOD. vol. 106, 943A-943A.

Fitzgibbon J, Smith L-L, Raghavan M, Smith ML, Debernardi S, Skoulakis S, Lillington D, Lister TA et al.(2005). Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leukemias. Cancer Res vol. 65, (20) 9152-9154.

Davies AJ, Lee AM, Taylor C, Clear AJ, Goff LK, Iqbal S, Cuthbert-Heavens D, Calaminici M et al.(2005). A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma. LEUKEMIA vol. 19, (8) 1459-1465.

Smith LL, Smith M, Goff L, Jenner M, Lister A, Fitzgibbon J, Bonnett D (2005). Development of a quantitative real-time PCR method for monitoring CEBPA mutations in normal karyotype acute myeloid leukaemia patient samples. EXPERIMENTAL HEMATOLOGY. vol. 33, 73-73.

Davies A, Iqbal S, Fitzgibbon J, Raghavan M, Chaplin T, Norton A, Lister A, Young B (2005). Homozygosity mapping by genome-wide SNP analysis of the transformation of follicular lymphoma (FL) to diffuse large B-cell lymphoma (TxDLBCL). ANNALS OF ONCOLOGY. vol. 16, 106-106.

Davies A, Arch R, Goff L, Gesk S, Foot N, Rosenwald A, Dyer M, Marinez-Climent J et al. (2005). Refinement of the 13q31-32 amplicon in B-cell non-Hodgkin's lymphoma by a simultaneous genomic and transcriptional approach. ANNALS OF ONCOLOGY. vol. 16, 80-80.

Suraweera N, Meijne E, Moody J, Carvajal-Carmona LG, Yoshida K, Pollard P, Fitzgibbon J, Riches A et al.(2005). Mutations of the PU.1 Ets domain are specifically associated with murine radiation-induced, but not human therapy-related, acute myeloid leukaemia. Oncogene vol. 24, (22) 3678-3683.

Lee A, Davies AJ, Clear A, Calaminici M, Matthews J, Norton A, Wright G, Staudt MLM et al. (2005). Tissue microarray is a useful tool in the evaluation of genes implicated in transformation of follicular lymphoma. JOURNAL OF PATHOLOGY. vol. 205, 11-11.

Smith ML, Arch R, Smith L-L, Bainton N, Neat M, Taylor C, Bonnet D, Cavenagh JD et al.(2005). Development of a human acute myeloid leukaemia screening panel and consequent identification of novel gene mutation in FLT3 and CCND3. Br J Haematol vol. 128, (3) 318-323.

Smith ML, Cavenagh JD, Lister TA, Fitzgibbon J(2004). Brief report - Mutation of CEBPA in familial acute myeloid leukemia. NEW ENGL J MED vol. 351, (23) 2403-2407.

Smith ML, Cavenagh JD, Lister TA, Fitzgibbon J(2004). Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med vol. 351, (23) 2403-2407.

Fitzgibbon J, Smith M, Arch R, Smith L-L, Bainton N, Neat M, Bonnet D, Cavenagh J et al.(2004). Development of a Human Acute Myeloid Leukaemia Screening Panel and Identification of Novel Gene Mutations. Blood vol. 104, (11) 2991-2991.

Fitzgibbon J, Smith M, Arch R, Smith LL, Bainton N, Neat M, Bonnet D, Cavenagh J et al. (2004). Development of a human acute myeloid leukaemia screening panel and identification of novel gene mutations. BLOOD. vol. 104, 817A-817A.

Ridler C, Smith M, Milne T, Ebrahim F, Macey M, Lister TA, Fitzgibbon J, Cavenagh JD et al. (2004). Flow cytometric FLT3 expression in acute leukaemias is of diagnostic value but does not correlate with ITD/D835Y mutation status. BLOOD. vol. 104, 823A-823A.

Fitzgibbon J, Smith M, Cavenagh J, Lister TA (2004). Mutation of CEBPA in familial acute myeloid leukaemia. BLOOD. vol. 104, 555A-555A.

Davies AJ, Lee AM, Taylor C, Clear AJ, Goff LK, Iqbal S, Cuthbert-Heavens D, Calaminici M et al.(2004). Sequential Time-Point Mutational Analysis of TP53 in Follicular Lymphoma Undergoing Transformation to Large B-Cell Lymphoma. Blood vol. 104, (11) 1361-1361.

Davies AJ, Lee AM, Taylor C, Clear AJ, Goff LK, Iqbal S, Cuthbert-Heavens D, Calaminici M et al. (2004). Sequential time-point mutational analysis of TP53 in follicular lymphoma undergoing transformation to large B-cell lymphoma. BLOOD. vol. 104, 382A-382A.

Last K, Perry J, Maharaj L, Strauss S, Davies A, Skoulakis S, Fitzgibbon J, Lister A et al. (2004). The induction of apoptosis in lymphoma cells by methylseleninic acid and selenodiglutathione. BLOOD. vol. 104, 686A-686A.

Lee A, Davies A, Clear A, Calaminici M, Matthews J, Norton A, Wright G, Staudt LM et al. (2004). Tissue microarray is a useful tool in the evaluation of genes implicated in transformation of follicular lymphoma. BLOOD. vol. 104, 624A-624A.

Last KW, Rohatiner AZS, Fitzgibbon J, Lister TA(2004). Serum selenium in lymphoma - In reply. J CLIN ONCOL vol. 22, (16) 3430-3430.

Nilsen H, An Q, Fitzgibbon J, Lister A, Lindahl T (2004). Complex phenotypes associated with uracil in DNA in mammals. BRITISH JOURNAL OF CANCER. vol. 91, S71-S71.

Iqbal S, Jenner MJR, Summers KE, Davies AJ, Matthews J, Norton AJ, Calaminici M, Rohatiner AZ et al.(2004). Reliable detection of clonal IgH/Bcl2 MBR rearrangement in follicular lymphoma: methodology and clinical significance. Br J Haematol vol. 124, (3) 325-328.

Goff LK, Iqbal S, Jenner MJ, Summers KE, Matthews J, Norton AJ, Calaminici M, Rohatiner AZS et al. (2003). Reliable detection of clonal IgH/Bcl-2 MBR rearrangement in follicular lymphoma: Methodology and clinical significance. BLOOD. vol. 102, 633A-633A.

Debernardi S, Van Delft F, Davies A, Lillington D, Smith M, Lister TA, Saha V, Young BD et al. (2003). The Wiskott-Aldrich-Syndrome family member 1 (WASF1) gene on 6q21 is down-regulated in specific AML cytogenetic subtypes. BLOOD. vol. 102, 582A-582A.

Last KW, Cornelius V, Delves T, Sieniawska C, Fitzgibbon J, Norton A, Amess J, Wilson A et al.(2003). Presentation serum selenium predicts for overall survival, dose delivery, and first treatment response in aggressive non-Hodgkin's lymphoma. J Clin Oncol vol. 21, (12) 2335-2341.

Snaddon J, Smith ML, Neat M, Cambal-Parrales M, Dixon-McIver A, Arch R, Amess JA, Rohatiner AZ et al.(2003). Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2. Genes Chromosomes Cancer vol. 37, (1) 72-78.

Smith ML, Snaddon J, Neat M, Cambal-Parrales M, Arch R, Lister TA, Fitzgibbon J(2003). Mutation of BRAF is uncommon in AML FAB type M1 and M2. LEUKEMIA vol. 17, (1) 274-275.

Davies A, Rosenwald A, Wright G, Henrickson SE, Hong Z, Fitzgibbon J, Last K, Norton A et al. (2002). Gene expression profiling in paired follicular lymphoma samples pre- and post-transformation to large B cell lymphoma. BLOOD. vol. 100, 315A-316A.

Jenner M, Summers K, Matthews J, Bradburn M, Dunning A, Wilson G, Lister TA, Fitzgibbon J (2002). Genetic risk factor for follicular lymphoma within the MHC region. BLOOD. vol. 100, 567A-567A.

Fitzgibbon J, Arch R, Davies A, Snaddon J, Neat M, Foot N, Summers K, Goff L et al. (2002). Refinement and evaluation of candidate genes within the 13q amplicon in germinal centre lymphoma. BLOOD. vol. 100, 189B-190B.

Jenner MJ, Summers KE, Norton AJ, Amess JA, Arch RS, Young BD, Lister TA, Fitzgibbon J et al.(2002). JH probe real-time quantitative polymerase chain reaction assay for Bcl-2/IgH rearrangements. Br J Haematol vol. 118, (2) 550-558.

Summers KE, Davies AJ, Matthews J, Jenner MJ, Cornelius V, Amess JA, Norton AJ, Rohatiner AZS et al.(2002). The relative role of peripheral blood and bone marrow for monitoring molecular evidence of disease in follicular lymphoma by quantitative real-time polymerase chain reaction. Br J Haematol vol. 118, (2) 563-566.

Snaddon J, Neat M, Fitzgibbon J, Smith ML, Rohatiner AZ, Lister TA, Amess JA(2002). Mutations in the runt homology domain of CBFalpha2 in myeloid malignancies with acquired trisomy 21. Cancer Genet Cytogenet vol. 136, (2) 151-152.

Summers KE, Goff LK, Wilson AG, Gupta RK, Lister TA, Fitzgibbon J(2001). The frequency of the Bcl-2/IgH t(14;18)(q32;q21) rearrangement in normal individuals implications for the monitoring of disease in patients with follicular lymphoma. LEUKEMIA vol. 15, (12) 2024-2024.

Jenner MJ, Summers KE, Norton AJ, Amess JA, Arch RS, Young BD, Lister TA, Fitzgibbon J et al.(2001). A universal strategy for quantifying Bcl-2/IgH breakpoints in follicular lymphoma. BLOOD vol. 98, (11) 126A-126A.

Snaddon J, Arch R, Sutcliffe K, Lister TA, Fitzgibbon J(2001). Identification of several novel polymorphisms in the low affinity FC inhibitory receptor FCGR2B. BLOOD vol. 98, (11) 164B-164B.

Snaddon J, Neat M, Smith ML, Rohatiner AZ, Lister TA, Fitzgibbon J(2001). Mutations in the runt domain of CBFA2 in myeloid malignancies with acquired trisomy 21. BLOOD vol. 98, (11) 195B-195B.

Snaddon J, Smith ML, Neat M, Arch R, Cambal-Parrales M, Amess JA, Rohatiner AZ, Lister TA et al.(2001). Mutations of CEBPA in acute myeloid leukaemia FAB-type M1 and M2. BLOOD vol. 98, (11) 195B-195B.

Davies AJ, Summers KE, Matthews J, Jenner MJ, Amess JA, Norton AJ, Rohatiner AZ, Fitzgibbon J et al.(2001). The relative role of peripheral blood and bone marrow for monitoring molecular evidence of disease in follicular lymphoma by quantitative real time PCR. BLOOD vol. 98, (11) 124A-125A.

Neat MJ, Foot N, Jenner M, Goff L, Ashcroft K, Burford D, Dunham A, Norton A et al.(2001). Localisation of a novel region of recurrent amplification in, follicular lymphoma to an similar to 6.8 Mb region of 13q32-33. GENE CHROMOSOME CANC vol. 32, (3) 236-243.

Foot N, Neat M, Jenner M, Goff L, Dunham I, Ross M, Fitzgibbon J, Lister TA(2001). Localisation of a novel region of amplification in follicular lymphoma tumours to a 24cR region of human chromosome 13. J MED GENET vol. 38, S44-S44.

Last KW, Cornelius V, Delves T, Fitzgibbon J, Wilson A, Rohatiner AZS, Lister TA(2001). Presentation serum selenium predicts for overall survival in patients with diffuse large B-cell (DLBC) lymphoma. BRIT J CANCER vol. 85, 59-59.

Summers KE, Goff LK, Wilson AG, Gupta RK, Lister TA, Fitzgibbon J(2001). Frequency of the Bcl-2/IgH rearrangement in normal individuals: implications for the monitoring of disease in patients with follicular lymphoma. J Clin Oncol vol. 19, (2) 420-424.

Jenner MJ, Matthews J, Summers K, Young BD, Fitzgibbon J, Lister A(2000). Application of real time PCR to establishing clonality of Bcl-2 rearrangements in patients with follicular lymphoma. BLOOD vol. 96, (11) 332A-332A.

Fitzgibbon J, Hill AS, Arch RS, Sutcliffe C, Summers KE, Lister A(2000). Identification of a novel polymorphism in the human FCGR2B gene: Correlation with response to Rituximab treatment in patients with follicular lymphoma. BLOOD vol. 96, (11) 179B-179B.

Neat M, Foot N, Jenner M, Goff L, Ashcroft K, Burford D, Dunham A, Fitzgibbon J et al.(2000). Localisation of a novel region of amplification in follicular lymphoma to an similar to 6.8 Mb region of human chromosome 13q32-33. BLOOD vol. 96, (11) 87A-87A.

Last KW, Cornelius VR, Delves T, Fitzgibbon J, Wilson A, Rohatiner AZ, Lister A(2000). Presentation serum selenium predicts for overall survival in patients with diffuse large B-cell (DLBC) lymphoma. BLOOD vol. 96, (11) 335A-335A.

Last KW, Goff LK, Summers KE, Neat M, Jenner M, Crawley C, Rohatiner AZ, Fitzgibbon J et al.(2000). Familial follicular lymphoma: a case report with molecular analysis. Br J Haematol vol. 110, (3) 744-745.

Fitzgibbon J, Neat MJ, Jones L, Foot N, Lister TA, Gupta RK(2000). Assignment of B-cell lymphoma 6, member B (zinc finger protein) gene (BCL6B) to human chromosome 17p13.1 by in situ hybridization. Cytogenet Cell Genet vol. 89, (3-4) 218-219.

Fitzgibbon J, Neat MJ, Foot N, Hill AS, Lister TA, Gupta RK(2000). Assignment of brain acid-soluble protein 1 (BASP1) to human chromosome 5p15.1-->p14, differential expression in human cancer cell lines as a result of alterations in gene dosage. Cytogenet Cell Genet vol. 89, (3-4) 147-149.

Fitzgibbon J, Grenzelias D, Matthews J, Lister TA, Gupta RK(1999). Tumour necrosis factor polymorphisms and susceptibility to follicular lymphoma. Br J Haematol vol. 107, (2) 388-391.

Halford S, Dulai KS, Daw SC, Fitzgibbon J, Hunt DM(1998). Isolation and chromosomal localization of two human CDP-diacylglycerol synthase (CDS) genes. Genomics vol. 54, (1) 140-144.